The lily family is composed of 280 to 300 genera made up of 4,000 to 4,600 different species. Ninety genera representing approximately 525 species are found in North America. Lilies are popular decorative plants and are also found in floral arrangements. The Convallaria genus, commonly called "lily of the valley," is well known as a toxic member of the lily family, although various genera of lily family plants can cause toxicity. 1 Lily of the valley (Convallaria majalis) takes its name from convallis (valley), leiron (lily), and majalis (May). Lily of the valley is a perennial herb that is 10 to 30 cm in height and has white flowers during April to June and red berries during July. Lily of the valley grows in the cooler climate of North America and also in Europe and certain parts of Asia. The entire plant is toxic, containing saponins responsible for digestive disorders and cardiac glycosides Upon completion of this activity you will be able to:
• list the potential clinical effect of convallatoxin, a cardiac glycoside that is the active toxic ingredient of lily of the valley.
• outline the effect of convallatoxin on LOCI digoxin assay and how this may affect therapeutic drug monitoring.
• describe use of Digibind to neutralize convallatoxin in vitro and apply measurement of free digoxin concentration to monitor this reaction.
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causing digitalis-like toxicity. The principle toxic cardiac glycoside found in lily of the valley is convallatoxin. There are several reports of lily of the valley poisoning. An 87-year-old woman suffering from advanced dementia was admitted to the hospital for ingestion of two sprigs of lily of the valley offered to her by the family. Fortunately the patient survived and was eventually discharged from the hospital. 2 Symptoms of digitalis-like toxicity in a family after accidental ingestion of lily of the valley plant has also been reported. 3 Moxley et al 4 reported the case of a 1-yearold mixed-breed dog after ingestion of lily of the valley plant; postmortem examination revealed leaf fragments of lily of the valley plant in the intestine. Lily of the valley extract is used in herbal medicine despite known toxicity of the plant. Herbalists in the 16th century recommended blossoms of lily of the valley soaked in wine for strengthening the memory, soothing inflamed eyes, and to ease symptoms of gout. 5 Lily of the valley extract is a component of many herbal preparations used as a tonic for the heart. Convallatoxin, the major cardiac glycoside present in lily of the valley, has digitalis-like properties by inhibition of sodium potassium adenosine triphosphatase, thereby causing a positive inotropic effect. 6 Convallatoxin is structurally similar to digoxin ❚Figure 1❚. Therefore, the possibility of rapid detection of convallatoxin in serum was studied using luminescent oxygen channeling technology-based digoxin assay (LOCI digoxin assay). Because a person taking digoxin may also take lily of the valley extract for its cardiotonic effect, the effect of lily of the valley extract on serum digoxin measurement using the LOCI digoxin assay was also studied. We further explored the possibility of neutralizing convallatoxin and cardiac glycosides of lily of the valley herbal preparation by using Digibind, the fab fragment of the polyclonal antidigoxin antibody.
Materials and Methods
Convallatoxin was purchased from the Sigma Chemical Company (St. Louis, MO). Lily of the valley herbal extract (Wise Woman Herbals, Creswell, OR) was obtained from a local herbal store in Houston, TX. LOCI is the digoxin assay used at Memorial Hermann Hospital, an 850-bed tertiary care hospital and level 1 trauma center located in the Texas Medical Center, Houston. LOCI digoxin assay kits were purchased from Siemens Diagnostics (Deerfield, IL) and assays were run on a Vista 1500 auto analyzer (Siemens Diagnostics) following the manufacturer's protocol. Centrifree Micropartition System filtration devices with a molecular weight cutoff of 30,000 Da were obtained from Amicon (Danvers, MA). The LOCI digoxin assay uses a specific mouse monoclonal antibody against digoxin and requires no sample pretreatment before assessment. The analytic measurement range of this assay is from 0.06 to 5.0 ng/mL of serum digoxin concentration. Standard solutions of convallatoxin were made in absolute ethanol, followed by further dilution with ethanol to prepare working standards.
Aliquots of digoxin-free serum pools were supplemented with either convallatoxin (10 ng/mL-2.5 µg/mL) or liquid extract of lily of the valley (5-20 µL/mL). Microliter quantities of convallatoxin ethanol working solution or lily of the valley extract were added to dry test tubes followed by evaporation of the solvent under a gentle stream of nitrogen and reconstitution with an aliquot of drug-free serum. The apparent digoxin concentrations were then measured using the LOCI digoxin assay. Each measurement was performed in triplicate and results are expressed as the mean and 1 standard deviation.
Digoxin serum pools were prepared by combining deidentified serum specimens from patients receiving digoxin that were submitted for therapeutic drug monitoring. The specimens were used after performing and reporting all results to the ordering clinicians, and after holding these specimens for 1 week as required by our laboratory protocol and guidelines of the University of Texas-Houston Institutional Review Board. Aliquots of the digoxin pool were supplemented with various amounts of pure convallatoxin or lily of the valley extract, with digoxin concentrations measured before and after supplementation.
To investigate whether convallatoxin or components of lily of the valley extract can be detected in vivo using the LOCI digoxin assay, BALB/c mice (Jackson Laboratories, Bar Harbor, ME) were orally gavaged with 50 µL of either 50 mg of convallatoxin (dissolved in saline containing 10% ethyl alcohol) or lily of the valley extract diluted 1:1 in normal saline. The vehicle control contained only normal saline with 10% alcohol. Three mice were used per group. Blood was drawn 1 and 2 hours after gavage and apparent digoxin concentrations were measured using the LOCI digoxin assay. No duplicate measurements of individual mice were possible because of limited specimen volume. Animal experiments were performed according to approved guidelines provided by the University of Texas Houston Health Science Center's committee on animal welfare. The ability of Digibind to bind convallatoxin or components of lily of the valley herbal extract was also explored in vitro. For this purpose, one drug-free serum pool was supplemented with convallatoxin (2.5 µg/mL) and another drug-free serum pool was supplemented with lily of the valley extract (10 µL of the extract/mL of serum). Digibind was then added to aliquots of these supplemented pools. After incubation at 37°C for 20 minutes, the free apparent digoxin concentration was measured in the proteinfree ultrafiltrate prepared by centrifuging each specimen using the Centrifree Micropartition System filter for 30 minutes at ×1,500g.
Statistical analyses were performed using the two-tailed Student t test. A statistically significant difference was considered at 95% confidence interval or higher (P < .05).
Results
Significant apparent digoxin concentrations using the LOCI digoxin assay were observed when aliquots of drug-free serum pool were supplemented with either convallatoxin or liquid extract of lily of the valley, indicating that the LOCI digoxin assay can be used for rapid detection of convallatoxin as well as digoxin-like immunoreactive components of lily of the valley herbal extract. For example, when an aliquot of drug-free serum pool was supplemented with 100 ng/mL of convallatoxin, the mean observed apparent digoxin level was 0.88 ng/mL, and with a higher amount of convallatoxin (1 mg/mL) the observed mean value was 4.25 ng/mL. When another aliquot of the drug-free serum pool was supplemented with lily of the valley extract to achieve a final concentration of 20 mL/mL, the observed mean apparent digoxin concentration was 1.99 ng/mL ❚Table 1❚. Based on the observed apparent digoxin concentration, convallatoxin concentration in the serum can be calculated using a polynomial equation: y = 89.9x 2 -524x + 617.3 where y represents concentration of convallatoxin in ng/mL and x represents observed apparent digoxin concentration observed by the LOCI digoxin assay (ng/mL). Using this equation, concentration of convallatoxin can be calculated in the lily of the valley extract. With 5 mL/mL of lily of the valley extract, the observed apparent digoxin concentration was 0.83 ng/mL, which represented convallatoxin concentration of approximately 154 ng/mL.
To investigate if convallatoxin can also be detected in vivo, mice were fed 50 mg/mL of convallatoxin. The observed apparent digoxin concentration 1 hour after feeding was 0.72 ng/mL (mouse 6) and 2 hours after feeding was 0.40 ng/mL ❚Table 2❚. Similar results were observed when mice were fed 50 mL of lily of the valley extract, indicating that the LOCI digoxin assay can be used to detect the presence of convallatoxin in serum in vivo after exposure to lily of the valley.
Because cross-reactivity of a substance should be tested in the presence of the primary analyte, 7 the effect of adding convallatoxin or lily of the valley extract to aliquots of a digoxin pool to test cross-reactivity of convallatoxin in the presence of the primary analyte digoxin was investigated. Bidirectional interference (negative interference with smaller amounts of convallatoxin and positive interference with higher amounts of convallatoxin) of convallatoxin with serum digoxin measurement using the LOCI digoxin assay was observed. Similar effects were also observed with lily of the valley extract. For example, mean digoxin concentration in the digoxin serum pool was 1.62 ng/ mL. When an aliquot of this digoxin pool was further supplemented with 50 ng/mL of convallatoxin, the observed digoxin concentration was significantly reduced to 1.06 ng/ mL. However, in the presence of 500 ng/mL of convallatoxin the observed digoxin concentration was 2.88 ng/mL, which was significantly greater than the original digoxin level of 1.62 ng/mL observed in the original digoxin pool. A similar bidirectional interference was observed when other aliquots of the same digoxin pool were supplemented with various amounts of lily of the valley extract ❚Table 3❚. The possibility of binding convallatoxin and digoxin-like immunoreactive substances present in lily of the valley extract using Digibind, the fab fragment of polyclonal antidigoxin antibody, was also studied. For this purpose, one drug-free serum pool was supplemented with 1 mg/mL of convallatoxin and another aliquot with 10 mL/mL of lily of the valley extract. Aliquots of each pool were further supplemented with various concentrations of Digibind representing in vivo concentrations observed in patients overdosed with digoxin and being treated with Digibind. After incubation, both total and free digoxin levels were determined using the LOCI digoxin assay. Digibind was capable of binding convallatoxin, as evidenced by significantly lower free digoxin level (including none detected level) in the presence of Digibind. For example, the total and free apparent digoxin levels in the drug-free serum pool supplemented with 1 mg/mL of convallatoxin were 4.55 ng/mL and 3.48 ng/mL, respectively. In the presence of 5 mg/mL of Digibind, the free apparent digoxin concentration was reduced to 1.66 ng/mL, indicating that Digibind is capable of binding free (non-protein bound) convallatoxin in serum. No apparent free digoxin level was observed in the presence of higher quantities of Digibind. Similar results were observed when another drug-free serum pool was supplemented with lily of the valley extract followed by further addition of Digibind ❚Table 4❚. The total digoxin measurements were affected by the presence of Digibind, but free digoxin measurements were not affected by Digibind because of the higher molecular weight (molecular weight of Digibind: approximately 46,200 Da where the cutoff of the filtration device was 30,000 Da). Digibind was absent in the protein-free ultrafiltrate. Elimination of Digibind interference in serum digoxin measurement by using free digoxin determination has been reported. 8 
Discussion
Accidental poisoning by lily of the valley in both animals and humans has been reported. In addition, it is possible that a person taking digoxin may also take lily of the valley herbal supplement due to increased and widespread use of herbal remedies. Therefore, a rapid diagnosis of poisoning with lily of the valley could be highly useful. The data presented here indicate that the LOCI digoxin assay can indirectly indicate the presence of convallatoxin in the serum measured as digoxin equivalent. In addition, convallatoxin can also be detected in vivo after mice are fed convallatoxin. However, confirmation with a specific method such as liquid chromatographymass spectrometry should be used to measure digoxin and confirm the presence of convallatoxin if suspected. Because convallatoxin has significant cross-reactivity with antidigoxin antibody used in the LOCI digoxin assay, it is possible that it may also cross-react with antidigoxin antibody used in other commercially available digoxin assays. Further studies are needed to investigate if LOCI digoxin assay is unique in its cross-reaction with convallatoxin or if other digoxin assays have similar capabilities.
Digoxin is a cardiac glycoside with a narrow therapeutic range. Therefore, it is important to accurately measure serum digoxin level. Immunoassays are widely used for digoxin measurement in clinical laboratories but digoxin assays also suffer from various interferences. Jones and Morris 9 analyzed LOCI, luminescent oxygen channeling technology-based; SD, standard deviation. a LOCI digoxin assay was performed on the Vista 1500 auto analyzer (Siemens Diagnostics, Deerfield, IL). b Significantly less than digoxin value of the digoxin pool by independent t test, two-tailed (P < .05). c Significantly greater than the value of the digoxin pool by independent t test, two-tailed (P < .05).
digoxin values in 36 plasma samples by sending aliquots to two different laboratories using different digoxin immunoassays. They observed clinically significant discordance in 39% of their samples and commented that interference of digoxin-like immunoreactive substances may explain only some of the discordance. Various other endogenous and exogenous factors are known to interfere with serum digoxin measurements using immunoassays. 10 Our results indicate that the LOCI digoxin assay is unsuitable for therapeutic drug monitoring of digoxin due to significant interferences of convallatoxin. According to the 2013 College of American Pathologists survey (first quarter), of 3,069 participating laboratories performing digoxin immunoassays, 493 are using LOCI digoxin assay on the Vista 1500 analyzer. Bidirectional (positive/negative) interference of convallatoxin in LOCI digoxin assay is interesting. As Valdes and Jortani 11 pointed out, such bidirectional interference is most likely caused by complex kinetic characteristics of the immunoreaction. Under equilibrium conditions, most crossreactivity results in a positive interference, but the demand for immunoassay results to be automated and available faster precludes such equilibrium chemistry, making bidirectional interference a possibility in the automated assays governed by nonequilibrium chemistry. In addition, a wash step might have contributed to negative interference by washing off bound interfering substance if present in low concentration during such a step. This opens up additional bound antibody sites available for label binding, thereby contributing to altered signal causing negative interference. In the presence of more interfering substances, such a wash off is not feasible, thus contributing to positive interference.
Digibind is useful in reversing life-threatening digitalis toxicity. However, Digibind is also capable of reversing various cardiac toxins such as oleandrin and bufalin (other herbal medicines) that have structural similarity to digoxin. 12 Camphausen et al 13 described a 7-year-old boy who presented to the hospital 6 hours after ingestion of oleander and was successfully treated with Digibind. Bandara et al 14 reviewed toxicity of oleander and usefulness of digoxin-specific fab fragment as useful therapy for oleander poisoning. Our results indicate that Digibind is also capable of binding convallatoxin in vitro.
In conclusion, this represents the first report of rapid detection of convallatoxin indirectly as digoxin-like immunoreactivity using the LOCI digoxin assay as well as in vitro binding of Digibind with convallatoxin. We further demonstrated that the LOCI digoxin assay is unsuitable for therapeutic drug monitoring of digoxin in a patient receiving digoxin and also self-medicated with an herbal supplement containing lily of the valley extract. 
